Iodine-125 vs palladium-103 for low-risk prostate cancer: Preliminary urinary functional outcomes from a prospective randomized multicenter trial

Journal of Brachytherapy International

Volumn 16, Issue 3, 2000, Pages 151-155

  Wallner, K ^a   Merrick, G ^a   True, L ^a   Kattan, M W ^a   Cavanagh, W ^a   Simpson, C ^a   Butler, W ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Brachytherapy; Prostate Carcinoma

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034489611     PISSN: 10944540     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Isotope selection for patients undergoing prostate brachytherapy
2. Dose-response study of iodine-125 and palladium-103 brachytherapy in a rat prostate tumor (Nb-AI-1)
3. Long-term complications with prostate implants: Iodine-125 vs palladium-103
4. Permanent implants using Au-198, Pd-103 and 1-125: Radiobiological considerations based on the linear quadratic model
5. Palladium-103 brachytherapy for prostate carcinoma
6. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance
7. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation
8. The American Urologic Association symptom index for benign prostatic hyperplasia
9. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation